Learning From Past Respiratory Infections to Predict COVID-19 Outcomes: Retrospective Study

Shengtian Sang1*, PhD; Ran Sun1*, PhD, RN; Jean Coquet1*, PhD; Harris Carmichael2, MD; Tina Seto3, MSc; Tina Hernandez-Boussard1, PhD, MPH, MSc

1Department of Medicine, Biomedical Informatics, Stanford University, Stanford, CA, United States
2Intermountain Health, Salt Lake City, UT, United States
3Technology and Digital Solutions, Stanford University, Stanford, CA, United States
*these authors contributed equally

Corresponding Author:
Tina Hernandez-Boussard, PhD, MPH, MSc
Department of Medicine
Biomedical Informatics
Stanford University
1265 Welch Rd, 245
Stanford, CA, 94305-5479
United States
Phone: 1 650 725 5507
Email: boussard@stanford.edu

Abstract

Background: For the clinical care of patients with well-established diseases, randomized trials, literature, and research are supplemented with clinical judgment to understand disease prognosis and inform treatment choices. In the void created by a lack of clinical experience with COVID-19, artificial intelligence (AI) may be an important tool to bolster clinical judgment and decision making. However, a lack of clinical data restricts the design and development of such AI tools, particularly in preparation for an impending crisis or pandemic.

Objective: This study aimed to develop and test the feasibility of a “patients-like-me” framework to predict the deterioration of patients with COVID-19 using a retrospective cohort of patients with similar respiratory diseases.

Methods: Our framework used COVID-19–like cohorts to design and train AI models that were then validated on the COVID-19 population. The COVID-19–like cohorts included patients diagnosed with bacterial pneumonia, viral pneumonia, unspecified pneumonia, influenza, and acute respiratory distress syndrome (ARDS) at an academic medical center from 2008 to 2019. In total, 15 training cohorts were created using different combinations of the COVID-19–like cohorts with the ARDS cohort for exploratory purposes. In this study, two machine learning models were developed: one to predict invasive mechanical ventilation (IMV) within 48 hours for each hospitalized day, and one to predict all-cause mortality at the time of admission. Model performance was assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, and negative predictive value. We established model interpretability by calculating SHapley Additive exPlanations (SHAP) scores to identify important features.

Results: Compared to the COVID-19–like cohorts (n=16,509), the patients hospitalized with COVID-19 (n=159) were significantly younger, with a higher proportion of patients of Hispanic ethnicity, a lower proportion of patients with smoking history, and fewer patients with comorbidities (P<.001). Patients with COVID-19 had a lower IMV rate (15.1 versus 23.2, P=.02) and shorter time to IMV (2.9 versus 4.1 days, P<.001) compared to the COVID-19–like patients. In the COVID-19–like training data, the top models achieved excellent performance (AUROC>0.90). Validating in the COVID-19 cohort, the top-performing model for predicting IMV was the XGBoost model (AUROC=0.826) trained on the viral pneumonia cohort. Similarly, the XGBoost model trained on all 4 COVID-19–like cohorts without ARDS achieved the best performance (AUROC=0.928) in predicting mortality. Important predictors included demographic information (age), vital signs (oxygen saturation), and laboratory values (white blood cell count, cardiac troponin, albumin, etc). Our models had class imbalance, which resulted in high negative predictive values and low positive predictive values.
Conclusions: We provided a feasible framework for modeling patient deterioration using existing data and AI technology to address data limitations during the onset of a novel, rapidly changing pandemic.

Methods

Study Design and Data Source
This retrospective study used data from electronic health records (EHRs) of patients admitted to the Stanford Healthcare Alliance (SHA) from January 1, 2008, to July 11, 2019. SHA is an integrated health system that includes an academic hospital, a community hospital, and a primary/specialty health care alliance. This study received approval from the institute’s Institutional Review Board (IRB). All source codes for this work are available at the Stanford Digital Repository [23].

Study Cohorts
This study included two retrospective cohorts: a COVID-19–like cohort (n=16,509) and a COVID-19 cohort (n=159).

COVID-19–like Cohort
The COVID-19–like cohort used for model training included patients hospitalized with a diagnosis of bacterial pneumonia, influenza, viral pneumonia, unspeciﬁed pneumonia, or ARDS, using International Classiﬁcation of Diseases codes (ICD-9 and ICD-10; Table S1 in Multimedia Appendix 1), between January 1, 2008, and July 11, 2019. These diseases were selected because of their similarity to COVID-19 in clinical manifestation, histological features, and disease progression [4,7,24]. Patients

Introduction

The SARS-CoV-2 virus, which causes the disease COVID-19, has infected almost 107 million people worldwide and is responsible for more than 2.3 million deaths [1]. Around the globe, patients with COVID-19 have a broad range of symptoms and disease severities. However, patients with COVID-19 demonstrate several symptoms that are striking in their commonality and nonspeciﬁcity to other well-known respiratory infections, such as pneumonia, influenza, and acute respiratory distress syndrome (ARDS) [2-5]. In fact, initial reporting of the disease indicated that most patients present with pneumonia-or influenza-like illnesses [6,7].

COVID-19 shares symptoms with other respiratory illnesses; from these diseases, we can learn about the clinical progression of patients, including the progression of patients presenting with severe hypoxemia followed by rapid deterioration, which often requires advanced life support such as invasive mechanical ventilation (IMV). Worldwide, the pandemic has left health systems struggling with capacity limits, especially regarding intensive care units (ICU) and mechanical ventilators [8,9]. Patients with COVID-19 remain on mechanical ventilation for an average of 10 to 20 days, further limiting the availability of this scarce resource [10,11]. Furthermore, an earlier study showed a high mortality rate of up to about 60% among critically ill patients [12]. The severity of cases has put great pressure on health systems, leading to a shortage of intensive care resources. Thus, understanding who will become critically ill and consume scarce resources as a result of this emerging disease can improve resource, hospital, and societal planning, and increase the number of lives saved.

However, given the novelty of COVID-19 and lack of clinical experience, the health care community is grappling for robust clinical data to learn about the disease. Under the appropriate assumptions, artificial intelligence (AI) may help with the planning of COVID-19 responses and guide clinical decisions in this time of uncertainty. Given the number of patients that may become infected with COVID-19, it is essential to understand who will be more likely to develop severe illness and need scarce resources at the time of presentation to the health care system, and AI can help with this determination. Indeed, AI technologies related to COVID-19 outcomes are emerging, as indicated in a recent published systematic review, with a majority of these studies conducted in China [13]. Predictive models using rule-based scoring tools and machine learning approaches have been applied to predict clinical deterioration in hospitalized patients and support health care providers in triaging patients when resources are limited [14-19]. However, there are many concerns and barriers to making this a reality [20], including uncertainty in the risk factors associated with disease progression, a limited number of patients whose data can be used to train and test models, and no public data sets available to test and validate models outside of a single health care setting. Of the COVID-19 AI studies published thus far, many have been designed and developed retrospectively on a small number of patient cases, limiting their validity and generalizability to other populations [15,21,22].

To help guide clinical decisions during the COVID-19 pandemic, we developed a framework to bootstrap AI models for outcomes of patients with COVID-19 using COVID-19–like cohorts to develop and train AI models to predict IMV within 48 hours and mortality using features associated with outcomes of patients with COVID-19. The COVID-19–like cohorts included patients diagnosed with bacterial pneumonia, influenza, viral pneumonia, and ARDS between 2008-2019. We tested the models’ performances on hospitalized patients with COVID-19. This framework may be particularly important in a novel and accelerated outbreak where clinicians and health care systems are forced to make difficult decisions without past experience of the specific disease at hand. In the void created by a lack of clinical experience with COVID-19, AI trained with data from COVID-19–like disorders may be an important way to bolster clinical judgment and decision making.
with complete missing lab data were excluded from the study (n=1712, 10.4%). For patients with multiple ICD codes for different conditions, the following rule was applied for disease categorization: influenza → viral pneumonia → bacterial pneumonia → unspecified pneumonia. Among these COVID-19–like cohorts, those who developed ARDS formed a separate COVID-19–like cohort.

**COVID-19 Cohort**

We included adults with a confirmed COVID-19 diagnosis who were hospitalized between March 1, 2020, and July 11, 2020. A confirmed COVID-19 diagnosis was defined as either a positive SARS-CoV-2 RNA detection test or a diagnosis code for COVID-19 (Table S1 in Multimedia Appendix 1). All patients were observed throughout their hospital encounter.

**Data Collection**

Patient demographics and clinical information were captured from EHRs. We selected the most relevant features identified from the literature [2,3,5], including demographics, existing comorbid conditions, smoking history, symptoms at initial presentation, coinfection with other respiratory pathogens, and laboratory values (Textboxes 1-3). The patient’s existing comorbidities, including cardiovascular disease, diabetes, cancer, hypertension, chronic respiratory disease, respiratory failure, and kidney disease, were determined over a 3-year period prior to hospital admission for the retrospective cohort. Laboratory values 2 weeks prior to and during the hospital stay were extracted for the retrospective and COVID-19 cohorts. Laboratory values on the day of IMV were excluded to ensure the values were not taken after IMV.
Textbox 1. Features included in the invasive mechanical ventilation and mortality model development (demographics and clinical characteristics).

| Demographics and clinical characteristics |
|------------------------------------------|
| • Age at admission (years)               |
| • Gender                                 |
| • Race/ethnicity                         |
| • Ever smoked (all life before admission)|

| Comorbidity present (3 years before admission) |
|------------------------------------------------|
| • Cancer                                       |
| • Chronic respiratory disease                  |
| • Cardiovascular disease                       |
| • Hypertension                                 |
| • Type 2 diabetes                              |
| • Respiratory failure                          |
| • Kidney disease                               |
| • Alzheimer disease                            |
| • Cirrhosis                                    |

| Symptoms (15 days before admission)            |
|------------------------------------------------|
| • Cough                                       |
| • Dyspnea                                     |
| • Tachypnea (respiratory rate >20)             |
| • Hypoxemia (oxygen saturation ≤90%)           |
| • Rhinorrhea                                  |
| • Nose congestion                             |
| • Fever (temperature >37 C/98.6 F)             |
| • Sputum                                      |
| • Pharyngitis (sore throat)                    |
| • Headache                                    |
| • Fatigue                                     |
| • Conjunctivitis                              |
| • Diarrhea                                    |
| • Anosmia                                     |
| • Myalgias                                    |
Textbox 2. Features included in the invasive mechanical ventilation and mortality model development (laboratory findings).

**Laboratory findings**
- White blood cell count, K/μL
- Lymphocyte count, K/μL
- Alanine aminotransferase, U/L
- Aspartate aminotransferase, U/L
- Creatinine, mg/dL
- Lactate dehydrogenase, U/L
- Creatine kinase, U/L
- Cardiac troponin, ng/mL
- D-dimer, ng/mL
- Prothrombin time, seconds
- Serum ferritin, ng/mL
- Procalcitonin, ng/mL
- Platelet count, K/μL
- C-reactive protein, mg/dL
- Total bilirubin, mg/dL
- Blood urea nitrogen, mg/dL
- Albumin, g/dL
- Oxygen saturation, mm Hg
- Fraction of inspired oxygen, %
- Sodium, mmol/L
- Potassium, mmol/L

Textbox 3. Features included in the invasive mechanical ventilation and mortality model development (coinfections).

**Coinfection (15 days before admission)**
- Adenovirus
- Chlamydia pneumoniae
- Coronavirus
- Influenza A
- Influenza B
- Metapneumovirus
- Mycoplasma pneumonia
- Parainfluenza 1
- Parainfluenza 2
- Parainfluenza 3
- Parainfluenza 4
- Rhinovirus/enterovirus
- Respiratory syncytial virus

**Outcome**
The outcome of interest was IMV in the next 48 hours and all-cause mortality. In the COVID-19–like cohort, the need for IMV in 48 hours was identified from the EHRs using the presence of IMV date and time. This time point was selected due to the rapid deterioration of disease conditions observed in patients with COVID-19. Deceased individuals who did not receive IMV during their hospital stay were considered nonintubated patients. All-cause mortality was identified using...
the death date recorded in the EHRs, including those who died during their hospital stay and within two weeks of hospital discharge.

**Artificial Intelligence Framework**

We developed a three-step framework to bootstrap machine learning models to predict IMV and mortality among hospitalized patients with COVID-19. Figure 1 illustrates the study design framework, including training data generation, model development, and model evaluation.

**Figure 1.** The methodological framework for selecting training data cohort, model development, and model evaluation for predicting intubation and mortality.

**Training Data Generation**

To determine the most appropriate COVID-19–like cohort for the prediction task, we explored different combinations of the 4 COVID-19–like cohorts (influenza, bacterial pneumonia, viral pneumonia, and unspecified pneumonia), including any single disease, any two diseases, any three diseases, and all four diseases combined to construct 15 training cohorts. Due to the differences between patients with COVID-19 and patients with ARDS, these COVID-19–like patients who developed ARDS were considered as an additional exploratory cohort to examine whether or not it could contribute to better prediction for the patients with COVID-19. Since we selected the best-performing machine learning model from each COVID-19–like cohort, 16 models were developed from the 16 COVID-19–like cohorts.

**Model Development**

**Data Preprocessing**

Features with missing values in the training set were imputed as –1. Due to the unbalanced data in training cohorts (Table S2 in Multimedia Appendix 1), oversampling approaches were used to generate synthetic samples for the minority class and to balance the positive and negative training set. These approaches included synthetic minority oversampling technique.
presented using SHapley Additive exPlanations (SHAP) values. Feature importance for predicting IMV and mortality were calculated using SHAP. For true positive and false negative cases, the terms were retrained with the best hyperparameters to predict the need for IMV and mortality, respectively.

Model Training

Each of the 16 preprocessed COVID-19–like cohorts were split into 70% training and 30% validation sets with stratified random sampling. We derived four machine learning algorithms, including SVM and three tree-based ensemble algorithms (decision tree, AdaBoost, and XGBoost). We selected three decision tree–based algorithms because they have previously been applied to predict clinical events in patients with respiratory diseases based on EHR data [16,26,27]. We included models that were frequently applied for clinical prediction of severe patient outcomes [16,26,28]. In total, two steps were involved in model training: (1) using the training data set, a 10-fold cross-validation strategy was used to train the machine learning models, while grid search technique was used to search all combinations of hyperparameters and determine the best hyperparameters, and (2) using all training data, the models were retrained with the best hyperparameters (obtained in step 1). The validation data were used to monitor the performance of the model to avoid overfitting in training data. The final model was derived when the performance of the model on the validation data set did not improve after 20 training iterations. The detailed processes of model training are presented in Figure S1 in Multimedia Appendix 1.

Model Evaluation

COVID-19–like Cohorts

The performance of the models on the training cohorts was compared using the area under the receiver operating characteristic curve (AUROC). The default threshold of 0.5 was selected for interpreting probabilities to class labels. For IMV, to be a true positive, the model had to predict the need for IMV within 48 hours with a risk score of ≥0.5, and the patient had to receive IMV within this time interval. If the risk score was ≥0.5 and the patient did not receive IMV in 48 hours, the patient was treated as a false positive. The inverse strategy was applied for true negative and false negative cases. For mortality, patients who died during the hospital course or within two weeks after discharge with a risk score of ≥0.5 were considered as true positives. The inverse strategy was applied for the true negative and false negative mortality cases. To interpret the model, feature importance for predicting IMV and mortality were presented using SHapley Additive exPlanations (SHAP) values [29].

COVID-19 Cohort

The best training cohort was selected based on model performance (ie, AUROC) on the COVID-19 cohort. To determine the feasibility of models trained on COVID-19–like cohorts to identify patients at high risk of IMV within 48 hours and all-cause mortality, we calculated the AUROC, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for patients with COVID-19.

Statistical Analysis

Descriptive statistics were used to compare the characteristics of the COVID-19–like and COVID-19 populations. An independent t test or Mann-Whitney U test were used wherever appropriate for comparing continuous features. The Pearson chi-square test was used for categorical features, and the Fisher exact test was used when the number in the cell was <5. Algorithms were developed using the training cohort and assessed on the independent validation cohort, which played no role in model development, by calculating the PPV and AUROC. Algorithms were further tested on the independent COVID-19 cohort. A threshold of 0.50 was set for each model, and PPV and all other threshold-dependent performance metrics were derived at this alert rate. As the PPV is threshold dependent, AUROC was also compared among models. We chose to present AUROC values because they are a threshold-independent measure of discrimination. Statistical significance for primary analysis was set at P<.05. All tests were two-tailed.

Results

Cohort Description

There were a total of 16,509 patients in the COVID-19–like cohorts, and 159 patients in the COVID-19 cohort (Table 1). Compared to the COVID-19–like cohorts with pneumonia and/or influenza, patients with COVID-19 were significantly younger (mean 56.9 [SD 20.3] years versus mean 65.8 [SD 19.3] years, P<.001), less often White (27% versus 58.2%, P<.001), and more often Hispanic (46.5% versus 13.6%, P<.001). In addition, patients with COVID-19 had a significantly smaller proportion of ever-smokers (29.6% versus 41.3%, P=.003) and fewer patients with COVID-19 had comorbidities (37.1% versus 67.1%, P<.001). There were significant differences in IMV rate and time to IMV between the COVID-19–like patients and patients with COVID-19; the patients with COVID-19 had a lower IMV rate (15.1% versus 23.2%, P=.02) and shorter time to IMV (2.9 [SD 3.9] days versus 4.1 [SD 7.3] days, P<.001). Additionally, we observed a significantly lower mortality rate in patients with COVID-19 compared to the COVID-19–like cohorts (P<.001).
Table 1. Comparison of patient demographics in COVID-19–like and COVID-19 cohorts.

| Characteristics | COVID-19–like cohort (n=16,509) | COVID-19 cohort (n=159) | P value |
|-----------------|---------------------------------|------------------------|---------|
|                 | Influenza (6.5)                 | Bacterial pneumonia (16.8) | Viral pneumonia (4.1) | Unspecified pneumonia (62.4) | Acute respiratory distress syndrome (10.1) | Total (16,509) | 159 |
| Age (years), mean (SD) | 63.9 (20.7) | 63.9 (19.5) | 63.8 (19.7) | 67.2 (18.9) | 62.3 (18.8) | 65.8 (19.3) | 56.9 (20.3) | <.001 |
| Gender, n (%) | Female | 557 (51.8) | 1212 (43.6) | 346 (50.8) | 4823 (46.8) | 730 (43.8) | 7668 (46.4) | 85 (53.5) | .08 |
|                  | Male | 519 (48.2) | 1567 (56.4) | 335 (49.2) | 5485 (53.2) | 933 (56.0) | 8839 (53.5) | 74 (46.5) | .001 |
| Race, n (%) | White | 585 (54.4) | 1674 (60.2) | 376 (55.2) | 6096 (59.1) | 872 (52.4) | 9603 (58.2) | 43 (27.0) | <.001 |
|                  | Asian | 178 (16.5) | 429 (15.4) | 123 (18.1) | 1640 (15.9) | 284 (17.1) | 2654 (16.1) | 23 (14.5) | <.001 |
|                  | Black | 72 (6.7) | 130 (4.7) | 38 (5.6) | 598 (5.8) | 110 (6.6) | 948 (5.7) | <10 (<6.3) | <.001 |
|                  | Other | 241 (22.4) | 546 (19.6) | 144 (21.2) | 1974 (19.2) | 399 (24.0) | 3304 (20.0) | 76 (47.8) | <.001 |
| Ethnicity, n (%) | Non-Hispanic | 898 (83.5) | 2321 (83.5) | 568 (83.4) | 8786 (85.2) | 1335 (80.2) | 13,908 (84.2) | 81 (50.9) | <.001 |
|                  | Hispanic | 170 (15.8) | 380 (13.7) | 106 (15.6) | 1325 (12.9) | 267 (16.0) | 2248 (13.6) | 74 (46.5) | <.001 |
| Insurance, n (%) | Private | 263 (24.4) | 605 (21.8) | 176 (25.8) | 2160 (21.0) | 414 (24.9) | 3618 (21.9) | 32 (20.1) | <.001 |
|                  | Public | 747 (69.4) | 1974 (71.0) | 477 (70.0) | 7447 (72.5) | 1129 (67.8) | 11,804 (71.5) | 101 (63.5) | <.001 |
|                  | Other | 66 (6.2) | 200 (7.2) | 28 (4.1) | 671 (6.5) | 122 (7.4) | 1087 (6.6) | 26 (16.4) | .003 |
|                  | Ever smoked, n (%) | 402 (37.4) | 1128 (40.6) | 283 (41.6) | 4375 (42.4) | 635 (38.1) | 6823 (41.3) | 47 (29.6) | <.001 |
|                  | At least one comorbidity | 771 (71.7) | 1745 (62.8) | 571 (83.8) | 7000 (67.9) | 997 (59.9) | 11,084 (67.1) | 59 (37.1) | <.001 |
|                  | Invasive mechanical ventilation, n (%) | 91 (8.5) | 1031 (37.1) | 95 (14.0) | 1811 (17.6) | 797 (47.9) | 3825 (23.2) | 24 (15.1) | <.001 |
|                  | Time to invasive mechanical ventilation (days), mean (SD) | 4.4 (7.2) | 3.8 (6.7) | 6.9 (12.9) | 4.0 (7.2) | 4.3 (7.4) | 4.1 (7.3) | 2.9 (3.9) | <.001 |
|                  | All-cause mortality, n (%) | 62 (5.8) | 513 (18.5) | 82 (12.0) | 1586 (15.4) | 541 (32.5) | 2789 (16.9) | <10 (<6.3) | <.001 |

aPercentages may not add up to 100 due to missing values.
bThe P value was calculated between the total of 4 retrospective COVID-19–like cohorts and the COVID-19 cohort.
cComorbidities include cardiovascular disease, diabetes, cancer, hypertension, chronic respiratory disease, respiratory failure, kidney disease, Alzheimer disease, and cirrhosis.

tables 2 and 3 compare symptoms at presentation and laboratory results during a hospital course between the COVID-19–like cohort and patients with COVID-19. Patients with COVID-19 experience a wider range and greater number of symptoms compared to the COVID-19–like cohort with pneumonia and influenza (P<.05). The average clinical laboratory results during hospitalization were also different (Table 3). The median laboratory values of D-dimer, lactate dehydrogenase, and ferritin elevated in hospitalized patients with COVID-19. Compared to the retrospective cohort of hospitalized patients with pneumonia and influenza, patients with COVID-19 had significantly higher values for lymphocyte count, platelet count, aspartate aminotransferase, albumin, lactate dehydrogenase, and ferritin, and lower values for white blood cell count, bilirubin, blood urea nitrogen, D-dimer, procalcitonin, creatinine, and prothrombin time.
Table 2. Comparison of symptoms at admission of the COVID-19–like cohort and patients with COVID-19.

| Symptoms at admission | COVID-19–like cohort (n=16,509), n (%) | COVID-19 cohort (n=159), n (%) | P value |
|-----------------------|----------------------------------------|--------------------------------|---------|
| Cough                 | 2643 (16.0)                            | 116 (73.0)                      | <.001   |
| Dyspnea               | 6087 (36.9)                            | 119 (74.8)                      | <.001   |
| Fever                 | 3147 (19.1)                            | 103 (64.8)                      | <.001   |
| Fatigue               | 2046 (12.4)                            | 67 (42.1)                       | <.001   |
| Myalgias              | 243 (1.5)                              | 52 (32.7)                       | <.001   |
| Hypoxemia             | 3910 (23.7)                            | 51 (32.1)                       | .01     |
| Headache              | 638 (3.9)                              | 28 (17.6)                       | <.001   |
| Diarrhea              | 1784 (10.8)                            | 29 (18.2)                       | .003    |
| Tachypnea             | 821 (5.0)                              | 57 (35.8)                       | <.001   |
| Pharyngitis (sore throat) | 53 (0.3)                          | 28 (17.6)                       | <.001   |
| Sputum                | 0 (0.0)                                | 26 (16.4)                       | N/A     |
| Rhinorrhea            | 0 (0.0)                                | 6 (3.8)                         | N/A     |
| Nasal congestion      | 62 (0.4)                               | 10 (6.3)                        | <.001   |
| Anosmia               | 8 (0.0)                                | 20 (12.6)                       | N/A     |

Table 3. Comparison of laboratory values of the COVID-19–like cohort and patients with COVID-19.

| Laboratory values | Values missing, n (%) | Median (IQR) | Values missing, n (%) | Median (IQR) | P value |
|-------------------|-----------------------|--------------|-----------------------|--------------|---------|
| White blood cell count, K/μL | 2767 (16.8) | 8.9 (5.7) | 0 (0.0) | 6.8 (3.5) | <.001 |
| Lymphocyte count, K/μL | 3386 (20.5) | 1.0 (0.8) | 2 (1.3) | 1.1 (0.7) | .008 |
| Platelet count, K/μL | 2768 (16.8) | 197.3 (134.5) | 0 (0.0) | 240.9 (110.7) | <.001 |
| Alanine aminotransferase, units/L | 3977 (24.1) | 32.0 (25.5) | 1 (0.6) | 33.2 (39.7) | .65 |
| Aspartate aminotransferase, units/L | 3803 (23.0) | 29.0 (24.9) | 1 (0.6) | 40.9 (28.6) | <.001 |
| Total bilirubin, mg/dL | 5125 (31.0) | 0.6 (0.5) | 2 (1.3) | 0.4 (0.3) | <.001 |
| Albumin, g/dL | 3744 (22.7) | 2.8 (1.0) | 1 (0.6) | 3.4 (0.5) | <.001 |
| Blood urea nitrogen, mg/dL | 2818 (17.1) | 19.0 (16.5) | 0 (0.0) | 13.5 (10.3) | <.001 |
| Troponin I, ng/mL | 12,026 (72.8) | 0.06 (0.18) | 135 (84.9) | 0.05 (0.14) | .82 |
| D-dimer, ng/mL | 14,717 (89.1) | 2311.8 (2646.5) | 141 (88.7) | 1125.5 (976) | .001 |
| Lactate dehydrogenase, units/L | 13,793 (83.5) | 293.0 (259.8) | 56 (35.2) | 369.0 (188.0) | <.001 |
| Ferritin, ng/mL | 14,763 (89.4) | 355.0 (819.2) | 55 (34.6) | 788.5 (875.8) | <.001 |
| Procalcitonin, ng/mL | 13,965 (84.6) | 0.5 (1.4) | 52 (32.7) | 0.1 (0.2) | <.001 |
| C-reactive protein, mg/dL | 15,225 (92.2) | 8.7 (13.7) | 71 (44.7) | 7.2 (10.2) | .30 |
| Creatine kinase, units/L | 13,668 (82.8) | 76.0 (143.5) | 93 (58.5) | 81.5 (161.1) | .61 |
| Sodium, mmol/L | 2751 (16.7) | 136.9 (4.8) | 0 (0.0) | 137.0 (4.3) | .56 |
| Potassium, mmol/L | 2750 (16.7) | 4.0 (0.5) | 0 (0.0) | 4.0 (0.5) | .97 |
| Creatinine, mg/dL | 2757 (16.7) | 1.0 (0.6) | 0 (0.0) | 0.8 (0.3) | <.001 |
| Prothrombin time, s | 6322 (38.3) | 15.2 (3.2) | 43 (27.0) | 13.6 (1.5) | <.001 |
| Oxygen saturation, % | 7107 (43.0) | 96.0 (2.5) | 0 (0.0) | 95.9 (2.4) | .10 |
| Fraction of inspired oxygen, % | 8125 (49.2) | 28.5 (10.0) | 35 (22.0) | 27.7 (13.4) | .44 |

Model Performance: Predicting 48-Hour IMV
The AUROCs of all models for predicting 48-hour IMV risk are illustrated in Figure 2. Algorithm discrimination and other performance metrics for the COVID-19–like cohorts are presented for each model in Table S3 in Multimedia Appendix 1. At the prespecified threshold of 0.5, the XGBoost classifiers achieved the highest AUROCs (range 0.772-0.905) compared to other machine learning classifiers in each of the 16 training cohorts for prediction of 48-hour risk for IMV. The best PPVs

https://www.jmir.org/2021/2/e23026
J Med Internet Res 2021 | vol. 23 | iss. 2 | e23026 | p. 9
(page number not for citation purposes)
ranged between 0.583 and 0.767, and all models had an accuracy of 0.724 or higher and specificity of 0.786 or higher. The model trained with the influenza cohort was one of the worst-performing models, with an AUROC of 0.772 and PPV of 0.583 for IMV.

**Figure 2.** Receiver operating characteristic curves for model performance on predicting 48-hour invasive mechanical ventilation risk in the COVID-19 cohort, stratified by COVID-19–like cohorts. ARDS: acute respiratory distress syndrome; ROC: receiver operating characteristic.

The pretrained models for 48-hour IMV prediction performed worse on the COVID-19 cohort than on the COVID-19–like cohorts. The model with the best performance on the new COVID-19 cohort was the XGBoost model trained on the viral pneumonia cohort (AUROC=0.826). The accuracy, precision, and sensitivity of the best model were 0.948, 0.423, and 0.289, respectively. Performance metrics for each model are presented in Table S4 in Multimedia Appendix 1. For negative cases at the patient-day level, the mean risk score was 0.09 (SD 0.12), with a minimum of 0.002 and a maximum of 0.859. For positive cases, the mean risk score was 0.31 (SD 0.23), with a minimum of 0.012 and a maximum of 0.823. At the patient level, the best-performing model was able to predict IMV in 48 hours for 7 of the 24 intubated patients with COVID-19. The model failed to predict the need for IMV in 48 hours for 17 patients (71%). Among the non-IMV patients, two were predicted to be at high risk of requiring IMV, although they were never intubated during hospitalization. Further details of the model hyperparameter optimization for predicting IMV can be found in Tables S5 and S6 in Multimedia Appendix 1.

**Model Performance: Predicting All-Cause Mortality**

Figure 3 and Table S7 in Multimedia Appendix 1 present detailed results of model performance for mortality prediction on the COVID-19–like cohorts. The XGBoost classifiers outperformed other machine learning classifiers in each of the 16 training cohorts for all-cause mortality prediction, with AUROC values ranging from 0.679 to 0.748.
Mortality prediction was better when testing on the COVID-19 cohort, with AUROC values ranging from 0.687 to 0.928. The best-performing model for the COVID-19 cohort was the XGBoost model trained on all 4 COVID-19–like cohorts (AUROC=0.928). The accuracy, precision, and sensitivity of the best model were 0.925, 0.286, and 0.222, respectively. The worst-performing model for the COVID-19 cohort was trained by using the pneumonia cohort, and achieved an AUROC of 0.687. Other results are presented in Table S8 in Multimedia Appendix 1. For all-cause mortality prediction at the patient level, the best-performing model predicted 22% of the deaths at the time of hospital admission. Further, our model predicted 5 deaths among the 109 patients discharged alive at the time of hospital admission.

**Manual Chart Review**

Manual chart review of 24 false positive and false negative cases was performed by author HC. Among the seven false positive cases for IMV prediction, one patient received IMV; however, this was not entered as structured data in the EHRs, therefore it was marked as a false positive for the model. Furthermore, two patients were extremely ill and close to receiving IMV. In the 17 false negative cases, 6 patients experienced rapid clinical deterioration in less than 24 hours or sometimes within 12 hours, and another 6 patients received scores that were close to the threshold. Additionally, our model incorrectly predicted the risk of death in 12 patients, including 5 false positive and 7 false negative cases. Based on the chart review, we confirmed that 3 of the 5 false positives were true false positives, while for the other two, the patients’ conditions were severe and they were identified by the clinician as having a higher risk of death.

**Algorithm Variable Importance**

To identify the most salient features driving model prediction, we calculated SHAP values for the best-performing model. Among the top features, elevated fraction of inspired oxygen, total bilirubin, white blood cell count, lymphocyte count, D-dimer, and cardiac troponin, and lower albumin, oxygen saturation, and platelet count favored the classifier to predict an IMV event. Other important features from the best prediction model are in Figure 4. For mortality, being older and having higher blood urea nitrogen, potassium, and high-sensitivity cardiac troponin, and low albumin, oxygen saturation, and platelet count favored the classifier to predict an IMV event. Other important features associated with increased mortality risk included elevated total bilirubin and lower platelet count (Figure 5).
Figure 4. SHapley Additive exPlanations (SHAP) scores for identifying important features for prediction of invasive mechanical ventilation, including demographic information, vital values, and laboratory values. The color indicates whether the value of the feature is high (red) or low (blue).

Figure 5. SHapley Additive exPlanations (SHAP) scores of the mortality prediction model. The color indicates whether the value of the feature is high (red) or low (blue).

Discussion

Principal Findings

In the clinical care of well-established diseases, literature and research are supplemented by the clinical judgment that is formed and refined through repeated episodes of care. Given the novelty of COVID-19, there is a lack of research evidence and clinical experience to inform clinical practice and guide care decisions. AI-enabled clinical decision support tools are promising to fill this gap and bolster clinical decision making. Early studies suggest that the disease manifestation, symptoms, and clinical course of COVID-19 resemble that of other respiratory infections, particularly pneumonia, influenza, and ARDS [5,30-32]. Due to the lack of robust, unbiased, representative data to train an AI model, we designed a framework to bootstrap existing retrospective data from COVID-19–like cohorts to predict IMV and all-cause mortality.

Our findings regarding the study cohort are consistent with previous international studies comparing patients with COVID-19 with patients previously hospitalized with other respiratory illnesses. The patients hospitalized with COVID-19 in our health system were younger and had fewer comorbidities than the COVID-19–like patients [33]. Patients with COVID-19 were less likely to have ever smoked compared to the COVID-19–like cohort. In addition, racial and ethnic minorities have been disproportionally affected by the disease, and we show similar trends in our health care system [32,34]. In addition to the variations in demographics and clinical outcomes, we
observed differences in symptoms at admission and laboratory values during the hospital stay. Importantly, significant differences were observed in IMV rates, time to IMV, and mortality rates between the two cohorts, with lower IMV and mortality rates in the patients with COVID-19 than in the COVID-19–like cohort, yet faster deterioration, as indicated by a shorter duration from admission to IMV.

The models, in general, performed well in the COVID-19–like cohorts, but less optimally in the COVID-19 cohort. Although the AUROC values of the best IMV and mortality prediction models in the COVID-19 cohort were good, the PPVs of both models were low, although the NPVs were high. Overall, the two models underestimated risk scores in patients with COVID-19. This can be explained by several factors. First, symptoms, laboratory values, and the proportions of missing data were different between COVID-19–like patients and patients with COVID-19, despite them sharing similar clinical manifestations and symptoms. Second, unlike the COVID-19–like cohorts, patients with COVID-19 had a broad spectrum of clinical manifestations, with critical courses that may involve fast deterioration and the need for IMV within 24 hours; thus, patients may have had limited signs of severe disease progression 48 hours prior to IMV. On the other hand, severe clinical circumstances may affect clinical decisions. Clinicians may be reluctant to put patients on a ventilator due to the complexity of and complications associated with this invasive procedure. Patients or family members might also be hesitant to consent to the procedure out of fear of losing control [35]. Sometimes, patients have a Do Not Intubate code status, indicating they do not want to receive IMV in the event of a life-threatening situation. All these factors challenge the performance of our model, particularly the PPV. The model made a positive prediction for patients who require IMV, yet patients may not receive it in the end due to the factors mentioned above, and these are therefore considered false positives.

Traditional machine learning evaluation criteria, such as AUROC and PPV, were used to assess the performance of predicting the risk of IMV and all-cause mortality at the patient-day level; however, there is a lack of standard criteria to evaluate the model at the patient level when there are also multiple day-level data. When reporting the patient-level prediction results, a “strict” criterion was selected: the model correctly predicted the case only when the alarm occurred at 48 hours before IMV. If the prediction occurred too early or too close to IMV, it was considered wrong for that patient. If correct cases were determined as at least one alarm before IMV for those who were finally intubated and no alarm for non-IMV patients, the model performance would be greatly improved. The use of different standards for analyzing patient-level results can have clinical significance. For example, if a patient is predicted to be intubated during hospitalization, the provider needs to be reminded to pay more attention to avoid the rapid deterioration of the patient’s condition. Therefore, our framework provides important insight into the deterioration of patients with COVID-19 and the timing of that deterioration. Further studies are needed to explore evaluation criteria for this novel, emerging disease.

The performances of our COVID-19–like models suggest that the deterioration in the COVID-19 population in our health system is more similar to viral pneumonia than other respiratory illnesses. These results support our evolving understanding of the clinical characteristics of this disease state and support evidence that patients with COVID-19 are less like ARDS patients than was originally believed [36]. Although the scientific community has been shifting practices of treating the ventilation needs of patients with COVID-19 away from mimicking ARDS treatment, this work may be the first indication that there is a detectable demographic and pathophysiologic difference in the presenting characteristics of COVID-19 as well as the response to therapy.

This work has several clinical applications. It is notable that this model could make for an excellent screening tool for clinical deterioration in the inpatient setting because the model has a high positive likelihood ratio and high specificity. This indicates that a positive result truly indicates an increased probability of clinical respiratory decline for those admitted to hospital with COVID-19, even if the individual PPV for that “patient-day” is low. The implementation of this model would allow for enhanced monitoring of patients likely to require advanced respiratory support, especially during surge settings when there is a strain on staffing with advanced infectious disease or pulmonary training.

Although there is lower ability to predict patients in need of IMV within 48 hours or all-cause mortality at the “patient-day” level with great precision, this work can also be used to identify patients who are not at risk of clinical escalation. This means that this model can be used as a screening tool in our population, offering providers some confidence in the current level of care being appropriate rather than using valuable hospital resources on enhanced monitoring for patients who are less likely to need advanced medical management for respiratory failure. Such information can help with resource allocation and help providers triage patients who are less likely to become critically ill. Given the extreme stress and burden the COVID-19 pandemic has placed on the health care system, particularly on frontline workers, identifying patients who may need less focused attention may reduce some of the burden for health care systems that are already stretched thin. We anticipate that this work could be implemented across health care systems and therefore provide all codes and software needed to deploy these models. The external validation of our framework across systems could help in elucidating the clinical course of COVID-19 by refining the model in populations over time.

**Limitations**

While we envision many possible applications of our framework, we also recognize several limitations. First, our data come from a single health care system, and the results may not generalize to other health care systems that may have a different patient population or clinical practice. External validation would be required to reinforce our conclusions. Second, the sample sizes of the COVID-19–like and COVID-19 cohorts are different, which may bias our comparison in terms of demographics and clinical characteristics. However, despite this difference, these patients share similar clinical manifestations, histological
features, and disease progression. Third, our data set contained a relatively small number of deaths, and the model performance on the COVID-19 cohort could be unstable based on the limited number of patients. Future work is needed to validate the mortality prediction in other settings. Finally, the prediction of the risk of mortality used data from admission, limiting the performance of the model. Despite these limitations, important lessons have been learned from our experience of using pretrained machine learning models for disease severity prediction. It is feasible to pretrain a model using an unseen disease-like cohort but this requires special caution. First, selecting the most appropriate cohort, one which is similar to the clinical manifestation, pathological features, and disease progression of the targeted disease population, is essential for developing a successful machine learning model. Second, based on the nature of the disease and the type of data that are available, determining the right time frame for your machine learning model is crucial. We failed to predict whether or not a patient with COVID-19 would need IMV during their hospital stay using data obtained at hospital admission. Predictions may be hampered by the rapid deterioration seen in some patients with COVID-19 and changes in laboratory results.

Conclusions
In conclusion, our work demonstrates the feasibility of using existing data infrastructure and AI technology to guide critical care resource allocation in the early stages of a disease outbreak when not many cases have been observed and there is a lack of training data. Although the spread of COVID-19 has been exponential worldwide, most individual health care systems do not have a comprehensive, diverse, readily available data set of patients with COVID-19, which is necessary to develop, train, and validate essential AI models that may be used to guide clinical care. To date, many COVID-19–related AI models distributed through the scientific community have been trained and “validated” on only a handful of patients. However, given the lack of knowledge related to COVID-19, there is an urgent need to learn as much as possible about the disease, even if from small nonrepresentative populations. The framework we describe provides a strategy to mitigate this lack of data by identifying how and what we can learn from other COVID-19–like diseases. As we will likely deal with another wave of COVID-19 cases and other pandemics in the future, having a framework to rapidly design and train predictive models will have eminent value. Although using these COVID-19–like cohorts to learn about and predict outcomes of patients with COVID-19 may not be ideal, they provide an unbiased pathway to help guide clinical decisions when faced with this novel disease.

Conflicts of Interest
None declared.

Multimedia Appendix 1
Supplementary materials.
[DOCX File , 64 KB-Multimedia Appendix 1]

References
1. Johns Hopkins Coronavirus Resource Center. URL: https://coronavirus.jhu.edu/map.html [accessed 2020-07-28]
2. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72,314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020 Apr 07;323(13):1239-1242. [doi: 10.1001/jama.2020.2648] [Medline: 32091533]
3. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, China Medical Treatment Expert Group for COVID-19. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med 2020 Aug 01;180(8):1081-1089 [FREE Full text] [doi: 10.1001/jamainternmed.2020.2033] [Medline: 32396163]
4. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020 Apr;8(4):420-422. [doi: 10.1016/s2213-2600(20)30076-x]
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 28;395(10229):1054-1062 [FREE Full text] [doi: 10.1016/S0140-6736(20)30566-3] [Medline: 32117076]
6. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020 Jun 06;395(10239):1763-1770 [FREE Full text] [doi: 10.1016/S0140-6736(20)31189-2] [Medline: 32442528]
7. Spellberg B, Haddix M, Lee R, Butler-Wu S, Holton P, Yee H, et al. Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020. JAMA 2020 May 19;323(19):1966-1967 [FREE Full text] [doi: 10.1001/jama.2020.4958] [Medline: 32232421]
8. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA 2020 Apr 28;323(16):1545-1546. [doi: 10.1001/jama.2020.4031] [Medline: 32167538]
9. Runyan ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. N Engl J Med 2020 Apr 30;382(18):e41. [doi: 10.1056/NEJMp2006141] [Medline: 32212516]

10. Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic’s Front Line. N Engl J Med 2020 May 14;382(20):1873-1875. [doi: 10.1056/NEJMp2005492] [Medline: 32187459]

11. Auld S, Caridi-Scheible M, Blum J, Robichaux C, Kraft C, Jacob J, Emory COVID-19 Quality and Clinical Research Collaborative. ICU and Ventilator Mortality Among Critically Ill Adults With Coronavirus Disease 2019. Crit Care Med 2020 Sep;48(9):e799-e804 [FREE Full text] [doi: 10.1097/CCM.0000000000004547] [Medline: 32452888]

12. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020 May;8(5):475-481 [FREE Full text] [doi: 10.1016/S2212-630X(20)30079-5] [Medline: 32105632]

13. Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 2020 Apr 07;369:m1328 [FREE Full text] [doi: 10.1136/bmj.m1328] [Medline: 32265220]

14. Guo Y, Liu Y, Lu J, Fan R, Zhang F, Yin X, et al. Development and validation of an early warning score (EWAS) for predicting clinical deterioration in patients with coronavirus disease 2019. MedRxiv Preprint published online on April 21, 2020. [doi: 10.1101/2020.04.17.2006491]

15. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis 2020 Sep 12;71(6):1393-1399 [FREE Full text] [doi: 10.1093/cid/ciaa414] [Medline: 32721369]

16. Vaid A, Somani S, Russak A, De Freitas JK, Chaudhry FY, Paranjpe I, et al. Machine Learning to Predict Mortality and Critical Events in a Cohort of Patients With COVID-19 in New York City: Model Development and Validation. J Med Internet Res 2020 Nov 06;22(11):e24018 [FREE Full text] [doi: 10.2196/24018] [Medline: 33027032]

17. Levy T, Richardson S, Coppa K, Barnaby DP, McGinn T, Becker LB, et al. Development and Validation of a Survival Calculator for Hospitalized Patients with COVID-19. MedRxiv Preprint published online on June 2, 2020. [FREE Full text] [doi: 10.1101/2020.04.22.20075416] [Medline: 32511640]

18. Zhang H, Shi T, Wu X, Zhang X, Wang K, Bean D, et al. Risk prediction for poor outcome and death in hospital in-patients with COVID-19: derivation in Wuhan, China and external validation in London. MedRxiv Preprint published online on May 3, 2020. [doi: 10.1101/2020.04.28.20082222]

19. Singh K, Valley T, Tang S, Li BY, Kamran F, Sjoding MW, et al. Validating a Widely Implemented Deterioration Index Model Among Hospitalized COVID-19 Patients. MedRxiv Preprint published online on April 29, 2020. [FREE Full text] [doi: 10.1101/2020.04.24.20079012] [Medline: 32511650]

20. Jewell NP, Lewnard JA, Jewell BL. Predictive Mathematical Models of the COVID-19 Pandemic: Underlying Principles and Value of Projections. JAMA 2020 May 19;323(19):1893-1894. [doi: 10.1001/jama.2020.6585] [Medline: 32297897]

21. Huang H, Cai S, Li Y, Li Y, Fan Y, Li L, et al. Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis. Front Med (Lausanne) 2020 Oct 5;7:557453 [FREE Full text] [doi: 10.3389/fmed.2020.557453] [Medline: 33123541]

22. Xie J, Hungerford D, Chen H, Abrams ST, Wang G, Wang Y, et al. Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19. MedRxiv Preprint published online on April 7, 2020. [doi: 10.1101/2020.03.28.20045997]

23. Sang S, Hernandez-Boussard T. Codes, models and synthesized data for paper ‘Learning from past respiratory infections to predict COVID-19 Outcomes: A retrospective study’. 2020 Jul 01. URL: https://doi.org/10.25740/vg665fp4193 [accessed 2020-07-01]

24. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020 May 12;323(18):1775-1776. [doi: 10.1001/jama.2020.4683] [Medline: 32203977]

25. Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP. SMOTE: Synthetic Minority Over-sampling Technique. J Artif Intell Res 2002 Jun 01;16:321-357. [doi: 10.1613/jair.953]

26. Ma F, Yu L, Ye L, Yao DD, Zhuang W. Length-of-Stay Prediction for Pediatric Patients With Respiratory Diseases Using Decision Tree Methods. IEEE J Biomed Health Inform 2020 Sep;24(9):2651-2662. [doi: 10.1109/jbhi.2020.2973285]

27. Yang P, Wu T, Yu M, Chen F, Wang C, Yuan J, et al. A new method for identifying the acute respiratory distress syndrome based on noninvasive physiological parameters. PLoS One 2020 Feb 5;15(2):e0226962 [FREE Full text] [doi: 10.1371/journal.pone.0226962] [Medline: 32023257]

28. Bolourani S, Brenner M, Wang P, McGinn T, Hirsch JS, Barnaby D, Northwell COVID-19 Research Consortium. A Machine Learning Prediction Model of Respiratory Failure Within 48 Hours of Patient Admission for COVID-19: Model Development and Validation. J Med Internet Res 2021 Feb 10;23(2):e24246 [FREE Full text] [doi: 10.2196/24246] [Medline: 33476281]

29. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. arXiv Preprint posted online on May 22, 2017. [FREE Full text]
30. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Mar 17;323(11):1061-1069 [FREE Full text] [doi: 10.1001/jama.2020.1585] [Medline: 32031570]
31. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol 2020 Oct 24;92(10):1902-1914 [FREE Full text] [doi: 10.1002/jmv.25884] [Medline: 32293716]
32. Gold JAW, Wong KK, Szablewski CM, Patel PR, Rossov J, da Silva J, et al. Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 - Georgia, March 2020. MMWR Morb Mortal Wkly Rep 2020 May 08;69(18):545-550 [FREE Full text] [doi: 10.15585/mmwr.mm6918e1] [Medline: 32379729]
33. Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrahão MTF, et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun 2020 Oct 06;11(1):5009 [FREE Full text] [doi: 10.1038/s41467-020-18849-z] [Medline: 33024121]
34. Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine 2020 Jun;23:100404 [FREE Full text] [doi: 10.1016/j.eclinm.2020.100404] [Medline: 32632416]
35. Macauley R. To trach or not to trach, that is the question. Paediatr Respir Rev 2019 Feb;29-9-13. [doi: 10.1016/j.prrv.2018.05.004] [Medline: 30665734]
36.Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does Not Lead to a ‘Typical’ Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2020 May 15;201(10):1299-1300 [FREE Full text] [doi: 10.1164/rccm.202003-0817LE] [Medline: 3228035]

Abbreviations

AI: artificial intelligence
ARDS: acute respiratory distress syndrome
AUROC: area under the receiver operating characteristic curve
IMV: invasive mechanical ventilation
NPV: negative predictive value
PPV: positive predictive value
SMOTE: synthetic minority oversampling technique
SVM: support vector machine

©Shengtian Sang, Ran Sun, Jean Coquet, Harris Carmichael, Tina Seto, Tina Hernandez-Boussard. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 22.02.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.